Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.55 |
| ▸ | TYMS | P04818 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | GRK5 | P34947 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | CDK8 | P49336 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1159414 | 0.86 | TYMS (0.48) | LMNAHPGDHAVCR2TYMSMAPK1 | |
| SCHEMBL7602915 | 0.82 | ALDH1A1 (0.53) | LMNAHPGDMAPK1CHEK1HSD17B10 | |
| SCHEMBL9952845 | 0.81 | LMNA (0.49) | LMNAHPGDHAVCR2MAPK1JAK2 | |
| SCHEMBL5358839 | 0.79 | PARP1 (0.47) | HPGDTYMSRPS6KA3ALDH1A1MAPT | |
| SCHEMBL6014173 | 0.79 | TYMS (0.51) | LMNAHPGDHAVCR2TYMSFLT3 | |
| SCHEMBL5313770 | 0.79 | LMNA (0.57) | LMNAHPGDHAVCR2TYMSJAK2 | |
| SCHEMBL30988528 | 0.79 | TYMS (0.51) | LMNAHPGDHAVCR2TYMSMAPK1 | |
| SCHEMBL3862742 | 0.79 | LMNA (0.47) | LMNAHPGDHAVCR2TYMSMAPK1 | |
| SCHEMBL22101352 | 0.79 | PRNP (0.48) | LMNAHPGDHAVCR2TYMSMAPK1 | |
| SCHEMBL9245492 | 0.79 | ALDH1A1 (0.40) | LMNAHPGDHAVCR2TYMSHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| WO-2025003694-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LIMITED (GB) | 2025-01-02 | — | — | WO | disclosed |
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
| US-7501428-B2 | e.g. 2-(1-hydroxymethyl-2-phenyl-ethylamino)-5-[1-quinazolin-6-yl-methylidene]-thiazol-4-one; cyclin-dependent kinases (CDKs)/serine-threonine protein kinases inhibitor; antiproliferative, anticarcinogenic, antitumor agent | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | LMNA 3964/4885HPGD 258/4885HAVCR2 152/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | LMNA 4606/4885HPGD 3343/4885HAVCR2 2926/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | LMNA 3964/4885HPGD 258/4885HAVCR2 152/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | LMNA 3964/4885HPGD 258/4885HAVCR2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.